Alkaloid Breakthrough Unlocks Cancer Drugs. First lab mastery of plant-derived anticancer titans bisleuconothine A and bousigonine B unlocks scalable synthesis of nature’s intricate molecular fortresses. A revolutionary organocatalytic cascade creates a versatile 3-ethylpiperidine scaffold in one pot. Bioinspired couplings then assemble dimeric and trimeric monoterpenoid indole alkaloids (MIAs) with atomic precision, slashing barriers to drug development.
Professor Hayato Ishikawa’s team at Chiba University has conquered the labyrinthine architectures of bisleuconothine A and bousigonine B. Isolated from plant bark in 2010, these oligomeric MIAs feature exquisitely fused rings and stereocenters that defy routine lab replication. The innovation is a novel, metal-free organocatalytic cascade reaction that efficiently builds a common 3-ethylpiperidine intermediate as a universal progenitor. Divergent fragments then unite via biomimetic couplings, yielding the first total enantioselective syntheses: 20 steps for bisleuconothine A and 21 for bousigonine B. This convergent-divergent blueprint promises a torrent of related MIAs.
Bisleuconothine A, a potent anticancer compound, has shown robust growth inhibition across various cancer cell lines, including breast (MCF7), lung (A549), and colorectal (HCT116). It induces apoptosis via caspase activation, autophagy through LC3 lipidation, and xenograft tumor suppression without scarcity issues.
This democratizes access to these “protein-protein interaction” disruptors, which are too bulky and contorted for conventional small-molecule drugs. Ishikawa’s group plans collective syntheses and biological evaluations, potentially leading to next-generation agents against resistant cancers.
Nature’s most guarded phytochemical treasures are now lab-reproducible, enabling development of bioactive oligomeric alkaloids with cutting-edge enantiocontrol. This paradigm shift accelerates cancer leads rooted in evolutionary wisdom.